Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Study design:
Single arm, prospective, experimental study. Due to ethical reasons and in order to adhere as much as possible to current clinical practice, the presence of a control arm is not planned. Due to the non-comparative nature of the study, no blinding of treatment is planned.
Age
0–12
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Children of either sexes, aged 0-12 years
Diagnosis of mono- or bilateral primary congenital glaucoma
IOP greater than or equal to 22 mmHg and lower than 27 mmHg
Only one previous ocular hypotensive surgical procedure for treatment of glaucoma among the following: goniotomy, trabeculotomy, trabeculotomy with adjunct of mitomycin C) (only for medical treatment at least one month before)
Parent informed consent to data processing (at registration)
Parent informed consent before any study procedure
You may not be if
Secondary glaucoma (Sturge-Weber syndrome, type I neurofibromatosis, retinoblastoma, steroid-induced glaucoma, etc.)
Presence of concomitant abnormalities of the anterior segment of the eye (cataract, iridocorneal dysgenesia, congenital uveal ectropion uvea, etc.)
Previous treatment with the study drugs
Presence of concomitant systemic diseases (asthma, hypertension, cardiac disease, renal failure, etc.) that needs treatment with drugs, that could influence IOP (steroids, beta-blockers, angiotensin-converting-enzyme inhibitor -inhibitors diuretics, etc.)
Abnormalities of the cornea that could influence IOP readings (marked cornea edema)
Clareo Health | Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma
